Tag: generic drugs

Bioequivalence testing proves generic drugs deliver the same active ingredient at the same rate and extent as brand-name versions. This science-based standard ensures safety, effectiveness, and massive cost savings - with over 90% of U.S. prescriptions filled with generics.

Despite FDA approval, generic drugs in the U.S. face average delays of 3.2 years before reaching patients due to patent litigation and complex regulatory tactics. Real-world examples from 2023-2025 show how brand companies use patent thickets to block competition, driving up costs and limiting access.